Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors
In conclusion, novel therapeutic perspectives are emerging for CML, holding the potential for substantial advancements in disease treatment.PMID:38488824 | DOI:10.1080/14656566.2024.2331778
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Authors: Alessandro Costa Emilia Scalzulli Ida Carmosino Claudia Ielo Maria Laura Bisegna Maurizio Martelli Massimo Breccia Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Drugs & Pharmacology | Immunotherapy | Leukemia | Stem Cell Therapy | Stem Cells